ATC
IOVA icon

Adirondack Trust Company’s Iovance Biotherapeutics IOVA Stock Holding History

Adirondack Trust Company’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-65
Closed -$2K – 420
2021
Q2 		$2K Hold
65
– – ﹤0.01% 382
2021
Q1 		$2K Hold
65
– – ﹤0.01% 378
2020
Q4 		$3K Buy
+65
New +$2.58K ﹤0.01% 346

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Adirondack Trust Company's IOVA Position: Q3 2021 in Review

Adirondack Trust Company sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 65 shares — an estimated $2K sold.

Adirondack Trust Company first reported a position in IOVA in Q4 2020 and held it in 3 quarters. The position peaked at $3K in Q4 2020. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

  • Adirondack Trust Company reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Adirondack Trust Company sold 65 Iovance Biotherapeutics shares in Q3 2021, an estimated $2K.
  • Adirondack Trust Company first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 3 quarters.
  • Adirondack Trust Company's Iovance Biotherapeutics position peaked at $3K in Q4 2020.
  • 243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Adirondack Trust Company's 13F filing for Q3 2021, filed 16 Nov 2021.